Palvella Therapeutics, Inc. Variable Lease, Cost
Palvella Therapeutics, Inc. (PVLA) reported Variable Lease, Cost of $12.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-03-31
- Palvella Therapeutics, Inc. variable lease, cost for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. variable lease, cost for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. variable lease, cost for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. variable lease, cost for the quarter ending 2023-12-31 was $203.00K, a 30.24% decline year-over-year.
- Palvella Therapeutics, Inc. variable lease, cost for fiscal 2025 was $12.00K.
- Palvella Therapeutics, Inc. variable lease, cost for fiscal 2023 was $679.00K, a 7.87% decline from fiscal 2022.
- Palvella Therapeutics, Inc. variable lease, cost for fiscal 2022 was $737.00K, a 0.27% decline from fiscal 2021.
- Palvella Therapeutics, Inc. variable lease, cost for fiscal 2021 was $739.00K, a 4.38% increase from fiscal 2020.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $12.00K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $203.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $203.00K derived: sum of 3 quarters · filed 2024-08-14 | $301.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $203.00K derived: sum of 2 quarters · filed 2024-05-15 | $301.00K derived: sum of 3 quarters · filed 2024-11-13 | $505.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $301.00K derived: sum of 2 quarters · filed 2024-11-13 | $505.00K derived: sum of 3 quarters · filed 2024-11-13 | $679.00K 10-K · filed 2024-03-29 |
| 2023-09-30 | $98.00K 10-Q · filed 2024-11-13 | $302.00K derived: sum of 2 quarters · filed 2024-11-13 | $476.00K 10-Q · filed 2024-11-13 | $779.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $204.00K 10-Q · filed 2024-08-14 | $388.00K 10-Q · filed 2024-08-14 | $681.00K derived: sum of 3 quarters · filed 2024-08-14 | $829.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $186.00K 10-Q · filed 2024-05-15 | $477.00K derived: sum of 2 quarters · filed 2024-05-15 | $625.00K derived: sum of 3 quarters · filed 2024-05-15 | $790.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $291.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $439.00K derived: sum of 2 quarters · filed 2024-03-29 | $604.00K derived: sum of 3 quarters · filed 2024-03-29 | $737.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $148.00K 10-Q · filed 2023-11-14 | $313.00K derived: sum of 2 quarters · filed 2023-11-14 | $446.00K 10-Q · filed 2023-11-14 | $649.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $165.00K 10-Q · filed 2023-08-10 | $324.00K 10-Q · filed 2023-08-10 | $501.00K derived: sum of 3 quarters · filed 2023-08-10 | $699.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $159.00K 10-Q · filed 2023-05-11 | $336.00K derived: sum of 2 quarters · filed 2023-05-11 | $534.00K derived: sum of 3 quarters · filed 2023-05-11 | $715.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $177.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $375.00K derived: sum of 2 quarters · filed 2023-03-31 | $556.00K derived: sum of 3 quarters · filed 2023-03-31 | $739.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $198.00K 10-Q · filed 2022-11-04 | $379.00K derived: sum of 2 quarters · filed 2022-11-04 | $562.00K 10-Q · filed 2022-11-04 | $733.00K derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $181.00K 10-Q · filed 2022-08-04 | $364.00K 10-Q · filed 2021-08-05 | $535.00K derived: sum of 3 quarters · filed 2022-08-04 | $727.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $182.00K 10-Q · filed 2022-05-11 | $354.00K derived: sum of 2 quarters · filed 2022-05-11 | $546.00K derived: sum of 3 quarters · filed 2022-05-11 | $702.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $364.00K derived: sum of 2 quarters · filed 2022-03-02 | $520.00K derived: sum of 3 quarters · filed 2022-03-02 | $708.00K 10-K · filed 2022-03-02 |
| 2020-09-30 | $192.00K 10-Q · filed 2021-11-02 | $348.00K derived: sum of 2 quarters · filed 2021-11-02 | $536.00K 10-Q · filed 2021-11-02 | $622.00K derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $156.00K 10-Q · filed 2021-08-05 | $344.00K 10-Q · filed 2021-08-05 | $430.00K derived: sum of 3 quarters · filed 2021-08-05 | $501.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $188.00K 10-Q · filed 2021-05-17 | $274.00K derived: sum of 2 quarters · filed 2021-05-17 | $345.00K derived: sum of 3 quarters · filed 2021-05-17 | $414.00K derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $157.00K derived: sum of 2 quarters · filed 2021-03-31 | $226.00K derived: sum of 3 quarters · filed 2021-03-31 | $293.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $71.00K 10-Q · filed 2020-11-04 | $140.00K derived: sum of 2 quarters · filed 2020-11-04 | $207.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $69.00K 10-Q · filed 2020-08-10 | $137.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $68.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |